Dr. Lal PathLabs (LALPATHLAB) Q3 25/26 earnings summary

Executive summary

• Achieved 10.6% year-on-year revenue growth in Q3 FY26 and 10.8% for the nine-month period, driven by organic growth, operational excellence, and network expansion in metro and Tier 3/4 cities.

• Launched Sovaaka, a personalized preventive healthcare platform, and expanded high-end diagnostics in oncology, genomics, and infectious diseases.

• SwasthFit preventive health packages contributed 26% to total revenue in 9M FY26, with growing adoption in smaller towns.

• Unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025, were approved and reviewed without qualification by auditors.

• Third interim dividend of INR 3.5 per equity share declared, with record date set for February 5, 2026, following a 1:1 bonus share issue.

Financial highlights

• Q3 FY26 consolidated revenue: INR 6,598 million (Rs. 660 crore), up from INR 5,967 million (Rs. 597 crore) in Q3 FY25 (10.6% growth).

• EBITDA before exceptional items: INR 1,790 million (Rs. 179 crore) in Q3 FY26 (27.2% margin), up 16.3% year-on-year.

• Profit after tax for Q3 FY26: INR 914 million (Rs. 91 crore, PAT margin 13.9%), compared to INR 981 million (Rs. 98 crore) last year.

• Earnings per share for Q3 FY26: INR 5.4, down from INR 5.8 in Q3 FY25; YTD EPS at INR 22.4.

• Net cash and cash equivalents: INR 1,411 crore as of December 31, 2025.

Outlook and guidance

• Management expects organic revenue growth to stabilize at 11%-12% for FY26, with potential for higher growth in future years.

• EBITDA margin guidance maintained at 27%-28% for the full year, even after accounting for one-time Labour Code costs.

• Focus on expanding network in underpenetrated markets, especially West and South India, and enhancing high-end test portfolio.

• Continued investment in digital platforms, technology upgrades, and preventive wellness programs to drive future growth.

• No price increases expected in the next 2-3 quarters following recent GST-related price cuts.